Anaplastic thyroid carcinoma (ATC) is the most aggressive and worst-prognosis form of thyroid cancer; although it accounts for only 1-2% of all thyroid cancers, it is responsible for 14-39% of thyroid cancer deaths. At diagnosis, the vast majority of patients have locally advanced disease — the tumor rapidly invades the trachea, esophagus, recurrent laryngeal nerve, and neck vessels. It typically occurs in patients over 60-70 years, often arising in the background of pre-existing differentiated thyroid carcinoma or multinodular goiter (anaplastic dedifferentiation). Median survival is 3-6 months. Histologically composed of highly pleomorphic, undifferentiated cells. BRAF V600E and TP53 mutations are common. Does not respond to radioactive iodine therapy; combined chemoradiation and targeted therapies (BRAF/MEK inhibitors) are applied.
Age Range
60-80
Peak Age
70
Gender
Female predominant
Prevalence
Rare
ATC develops in most cases through dedifferentiation of pre-existing differentiated thyroid carcinoma (papillary or follicular) — accumulation of TP53, TERT promoter, and PIK3CA mutations on a background of BRAF V600E mutation causes tumor cells to lose thyroid differentiation characteristics. TP53 loss eliminates cell cycle control, leading to aggressive proliferation. Since tumor cells lose NIS (sodium-iodide symporter) expression, they cannot concentrate iodine — therefore appearing as cold nodules on scintigraphy and being resistant to RAI therapy. Rapid growth and extensive necrosis result from the tumor outgrowing its vascular supply — reflected on imaging as heterogeneous enhancement, large necrotic areas, and irregular margins. The infiltrative growth pattern causes the tumor to directly invade surrounding structures (trachea, esophagus, carotid sheath) without respecting tissue planes — seen as extensive extrathyroidal extension on CT and MRI. Necrotic areas show diffusion restriction on DWI, while solid viable areas demonstrate marked diffusion restriction due to high cellularity.
Rapidly growing thyroid mass within weeks-months, usually >5 cm, heterogeneously enhancing with extensive necrotic areas; with extensive invasion of trachea, esophagus, and neck vessels. This combination is virtually pathognomonic for anaplastic thyroid carcinoma — especially in patients >60 years with prior known thyroid disease history.
On ultrasonography, a large (usually >4 cm), markedly heterogeneous, predominantly hypoechoic mass. The mass extends beyond the thyroid capsule into surrounding structures — invasion of strap muscles, tracheal wall, jugular vein, or carotid artery vicinity may be seen. Internal necrotic/cystic areas are frequently observed. Margins are irregular and indistinct. Thyroid contour is disrupted with normal thyroid tissue displaced or completely invaded by the mass.
Report Sentence
A ... mm markedly heterogeneous, predominantly hypoechoic mass is seen in the thyroid, extending beyond the thyroid capsule into surrounding soft tissues; with necrotic areas and irregular margins, anaplastic thyroid carcinoma should be primarily considered.
Irregular, chaotic vascular pattern on color Doppler: increased intranodular vascularity in solid areas, avascular zones in necrotic areas. The vascular pattern cannot be strictly classified as intranodular or perinodular — it is chaotic and disorganized. Vascular flow may also be seen in invasive components extending into surrounding structures.
Report Sentence
Color Doppler examination demonstrates a chaotic vascular pattern within the mass, with increased intranodular vascularity in solid areas and avascular zones in necrotic areas.
On contrast-enhanced CT, a large (usually >5 cm) heterogeneously enhancing mass in the thyroid region. Solid components show prominent enhancement while extensive necrotic/cystic areas do not enhance. Tracheal deviation or invasion (luminal narrowing, wall irregularity), obliteration of fat planes adjacent to the esophagus, carotid artery/jugular vein encasement or invasion, and strap muscle invasion are clearly evaluated. Calcifications may be present (remnants of prior differentiated carcinoma).
Report Sentence
A ... mm heterogeneously enhancing mass with extensive necrotic areas is seen in the thyroid region, [deviating/invading] the trachea, with obliteration of fat planes adjacent to the [esophagus/carotid artery/jugular vein]; anaplastic thyroid carcinoma should be primarily considered.
On T2-weighted images, the mass shows heterogeneous signal intensity. Solid tumoral areas show intermediate-to-low T2 signal (due to high cellularity), necrotic/cystic areas show high T2 signal, and hemorrhagic components show variable signal. Extrathyroidal extension is clearly evaluable on T2 — particularly tracheal and esophageal invasion, laryngeal nerve involvement, and prevertebral fascia relationship are better visualized on MRI than CT.
Report Sentence
A mass with heterogeneous signal intensity on T2-weighted images is seen in the thyroid region, with intermediate-to-low signal in solid areas and high signal in necrotic areas; the mass demonstrates invasion of the [trachea/esophagus/prevertebral fascia].
Solid tumor areas show marked diffusion restriction on diffusion-weighted imaging (DWI) — high signal at high b-values (b=800-1000), low signal on ADC map (ADC <1.0 × 10⁻³ mm²/s). This finding reflects the high cellularity of the tumor. Necrotic areas do not show diffusion restriction (high ADC values).
Report Sentence
The solid components of the mass demonstrate marked diffusion restriction on diffusion-weighted imaging (low ADC values), consistent with high cellularity and supporting aggressive malignant pathology.
The thyroid mass shows no radiopharmaceutical uptake on I-123 or Tc-99m pertechnetate scintigraphy (cold region). Tumor cells cannot concentrate iodine due to loss of NIS expression. This finding indicates the tumor will not respond to RAI therapy and is important for therapeutic planning.
Report Sentence
No radiopharmaceutical uptake is observed at the location of the mass in the thyroid [right/left] lobe on I-123 scintigraphy (cold region), consistent with NIS expression loss and resistance to RAI therapy.
On non-contrast CT, tracheal lumen narrowing, tracheal wall thickening or irregularity, and tracheal cartilage destruction can be assessed. Tracheal invasion is the most serious local complication of ATC and can lead to airway obstruction. Greater than 50% narrowing of the tracheal lumen indicates a clinical situation requiring emergent airway management.
Report Sentence
The thyroid mass demonstrates tracheal invasion with approximately ...% narrowing of the tracheal lumen and [right/left/anterior] wall cartilage destruction; emergent evaluation for airway safety is required.
Criteria
Diagnosed directly as anaplastic carcinoma without prior known thyroid carcinoma history. Clinically presents with rapidly growing neck mass. No differentiated component found on histopathology.
Distinct Features
Worse prognosis. Usually presents >5 cm. High rate of distant metastases at diagnosis (50% — lung, bone). May show more homogeneous necrosis pattern on imaging.
Criteria
Anaplastic transformation of pre-existing papillary or follicular carcinoma. Differentiated and anaplastic components coexist on histopathology. BRAF V600E mutation is common (especially in those arising from papillary carcinoma).
Distinct Features
Rapid size increase in an existing thyroid nodule on imaging. Calcifications may be present as remnants of prior carcinoma. Slightly better prognosis (chance of earlier diagnosis). If BRAF V600E positive, candidate for BRAF/MEK inhibitor therapy (dabrafenib+trametinib).
Criteria
Anaplastic carcinoma arising in a background of long-standing multinodular goiter. Recognized by rapid growth of a dominant nodule within the goiter. Generally more common in endemic goiter regions.
Distinct Features
On imaging, a rapidly growing dominant mass in the background of multinodular goiter. Unlike other nodules, shows necrosis and extrathyroidal extension. 'Sudden growth of a goiter that has been present for years' is typical in patient history.
Distinguishing Feature
MTC has a slower course, coarse calcifications are prominent, elevated serum calcitonin is diagnostic. ATC grows very rapidly (<6 months), shows extensive necrosis and extrathyroidal invasion. Survival is measured in years for MTC but months for ATC.
Distinguishing Feature
Thyroid lymphoma usually arises in Hashimoto thyroiditis background, appears as homogeneous hypoechoic mass, necrosis is less prominent. ATC is much more heterogeneous with extensive necrotic areas and extrathyroidal invasion more dominant. Core biopsy/flow cytometry is diagnostic for lymphoma.
Distinguishing Feature
Papillary carcinoma is typically a slowly growing, well-defined or mildly irregular-margined nodule with microcalcifications. ATC grows very rapidly, shows extensive necrosis and widespread extrathyroidal invasion. 10-year survival of papillary carcinoma is >95% while median survival of ATC is 3-6 months.
Distinguishing Feature
Thyroid metastases usually appear as multiple nodules in the context of known primary malignancy history. ATC typically presents as a solitary, giant mass with much more aggressive local invasion. Metastases preserve histological features of the primary tumor while ATC is dominated by completely undifferentiated cells.
Urgency
emergentManagement
surgicalBiopsy
NeededFollow-up
specialist-referralATC is a diagnosis requiring emergent evaluation — immediate assessment needed due to risk of airway obstruction. Tissue diagnosis should be obtained by core biopsy (FNA is insufficient). BRAF V600E mutation testing should be performed — if positive, neoadjuvant dabrafenib+trametinib (BRAF/MEK inhibitors) response rate can reach 60%. Surgery is recommended only if R0/R1 resection is feasible. Combined chemoradiation (doxorubicin-based) is the standard approach. Targeted/immunotherapy agents such as lenvatinib and pembrolizumab are being evaluated in clinical trials. If tracheal invasion is present, emergent airway management must be ensured (tracheostomy may be required).
Anaplastic thyroid carcinoma is the most lethal thyroid cancer (median survival 3-6 months). It does not respond to RAI therapy. Treatment is usually palliative (radiotherapy + chemotherapy). Surgery is considered only for limited disease. Targeted therapy (dabrafenib + trametinib) is promising in BRAF V600E-positive cases.